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Adipose tissue has pleiotropic functions beyond lipid and energy metabolism. Adipose tissue secretes bioactive proteins, termed 
adipokines, which act through auto-, para- and endocrine pathways. These ensure multidirectional communications between the 
adipose and other tissues and organs. In obesity, an increased production of various adipokines leads to dysfunctions in food intake, 
immunity, insulin sensitivity, angiogenesis, hemostasis, and glucose and lipid metabolism, all of which linked to the pathogenesis 
of cardiometabolic diseases, including atherosclerosis, type 2 diabetes mellitus, and metabolic syndrome. Notable exceptions are 
adiponectin, nerve growth factor and interleukin-10, which circulating levels are decreased in these diseases. Here, we highlight 
some areas of adipobiology that may be implicated in the development of therapeutic progress through adipopharmacological 
studies on adipokines and other adipose tissue-derived molecules. Biomed Rev 2006; 17: 73-87.
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INTRODUCTION
Our knowledge of adipobiology of obesity and related cardi-
ometabolic diseases (CMD), such as atherosclerosis, hyper-
tension, type 2 diabetes mellitus (T2DM) and the metabolic 
syndrome, has undergone major expansion during the past 
decade. The striking point is that adipocytes and nonfat cells 
of the adipose tissue have gained the status of endocrine cells 
of numerous signaling proteins termed adipokines (1-3). 
Consequently, “adipopharmacology” was introduced as a 
filed of adipotargeting research aimed at drug discovery, also 
in CMD (2). 
This review outlines the adipopharmacology of adipokines, 
with special reference to aidponectin, plasminogen activator 
inhibitor-1 (PAI-1), tumor necrosis factor-alpha (TNF-α), 
interleukin-6 (IL-6), monocyte chemoattractant protein-1 
(MCP-1/CCL2), angiotensin II (AngII), leptin, and resistin. 
An adipocentric view is also addressed to (i) currently-used 
drugs such thiazolidinediones (TZDs) and statins, and (ii) 5’-
AMP-activated protein kinase (AMPK) and sirtuin 1 as novel 
adipopharmacological targets. 
Biomedical Reviews 2006; 17: 73-87.
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ADIPOBIOLOGY
“Adipobiology” connotes the study of the molecular and cel-
lular biology of the adipose tissue in health and disease (1). 
Adipose tissue is represented by white and brown subtypes. 
Here we focus on the biology of white adipose tissue (“white” 
adipobiology). The main cellular components of this tissue are 
mature, lipid-filled adipocytes, lipid-free preadipocytes, stro-
movascular cells and associated immune cells (macrophages, 
mast cells, and lymphocytes) (1,3). Adipocytes (fat cells) from 
lean humans have an average cell diameter of approximately 
70 µm, whereas fat cells from obese subjects can amount to a 
mean diameter of about 120 µm (4). There is continuing debate 
on the extent to which there is inter-convertibility between 
white and brown adipose tissue (5). Marked regional differ-
ences in adipose metabolism have been reported (6). 
The cellular development associated with adipocyte growth 
involves both hypertrophy and hyperplasia. Hyperplasia 
including adipogenesis results from the recruitment of new 
adipocytes from precursor cells in adipose tissue and involves 
the proliferation and differentiation of preadipocytes. Both 
adipocyte hypertrophy and hyperplasia occur in association 
with positive energy balance (energy intake in excess of energy 
expenditure) during normal growth and during the develop-
ment of obesity, with hypertrophy often preceding hyperplasia 
(4-6). However, the adipocyte has not an unlimited capacity 
for size expansion, and increases in fat cell number occur even 
during adulthood. When adipose tissue development in genetic 
or diet-induced obese animals is monitored over time, it is 
generally observed that increases in the adipocyte size precede 
increases in adipocyte number (7). It was suggested that there 
might be a “maximum cell size”. According to “critical fat 
cell size hypothesis”, enlarged adipocytes produce and release 
paracrine factors which control preadipocyte proliferation 
involved in the development of obesity (8).
It is traditionally known that adipose tissue serves as a lipid 
storage organ in the form of triglycerides (TG), which is the 
most efficient way to store calories. The functional idea was
that in case of a chronic positive energy balance, the excess 
calories are converted into TG mainly under the control of 
insulin, while in case of undernutrition and higher energy 
demand, TG are rapidly mobilized upon increased secretion 
of catecholamines and other lipolytic hormones (9). 
Because more than 90% of the adipocyte volume consists 
of TG, changes in adipocyte volume depend on the balance 
between synthesis (lipogenesis) and breakdown (lipolysis) of 
TG (10). There are distinct age-dependent variations in adipos-
ity, which are measured by body mass index (BMI) and other 
anthropometric criteria (11).
A SIMILARITY AT EXTREMITY: LIPODYSTROPHY VERSUS 
OBESITY 
Presence of average amount and functionally active adipose 
tissue is crucially important for good health, including the 
regulation of lipid and energy metabolism. From the study 
of sterol response element-binding protein-1c (SREBP-1c)-
deficient mice “we learned that too much fat is bad and so is
not enough fat. The punch line here is that a little fat is good”, 
quoting Charles Vinson, a co-author of this study (12). Extreme 
ends of adipose mass growth, obesity and lipodystrophy, result 
in almost similar clinical metabolic disorders (12-15). 
Lipodystrophies
Lipodystrophies are rare acquired and genetic disorders 
characterized by the selective loss of adipose tissue. Despite 
marked phenotypic heterogeneity among the different types of 
lipodystrophies, most of them predispose to metabolic compli-
cations seen in patients with obesity, such as insulin resistance, 
T2DM, hepatic steatosis, and dyslipidemia (12).
The underlying mechanisms that cause insulin resistance 
and the metabolic syndrome in patients with obesity and lipod-
ystrophies may be similar. For example, in patients with severe 
forms of obesity and lipodystrophies, there may be limitation 
in further storage of TG in adipose tissue, which results in 
diversion of TG to aberrant sites such as the liver and skeletal 
muscles and results in insulin resistance (11).
Currently, an acquired form of lipodystrophy occurs in 
HIV infected patients treated with highly active antiretroviral 
therapy that contains HIV-1 protease inhibitors (HIV-1-PI). 
The latter have been reported to inhibit adipogenesis, increase 
lipolysis, and decrease glucose uptake, thus resulting in HIV-
related adipose tissue redistribution syndrome (15-15a). Im-
portantly, SREBP-1 levels may be altered in both the liver and 
adipose tissue of animals treated with HIV-1-PI, and may be a 
pathogenetic mechanism of this kind lipodystrophy, because 
SREBP-1c overexpression in adipose tissue has been reported 
to cause lipodystrophy (15). 
Obesity
Generally, obesity can develop when energy intake is in excess 
of energy expenditure, differences in input and output being 
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buffered primarily by changes in the fat stores (16). Today, (i) 
obesity may be defined as a tumor-like expansion of adipose 
tissue (16), (ii) obese adipose tissue is a human body’s largest 
source of endocrine protein and steroid signals (3), and (iii) 
upregulation of some of these signals being of pro-inflamma-
tory nature is increasingly implicated in the pathogenesis of 
obesity-related, low-graded inflammatory disorders, including
CMD (2,3).
With TG constituting ≥85% of the tissue weight, there be-
ing only a thin area of cytoplasm between the fat droplet and 
the plasma membrane of the adipocyte. There are some 14 
members of the facilitative glucose transporter gene family 
(gene name SLC2A), and white adipocytes appear to express as 
many as eight members: GLUT1, GLUT3, GLUT4, GLUT5, 
GLUT8, GLUT10, GLUT12, H+-coupled myoinositol trans-
porter (17-19). These glucose transporters are highly important 
for glucose buffering and de novo lipid synthesis from carbohy-
drates. Moreover, direct measurements in humans by isotopic 
techniques under conditions of energy balance revealed that 
the contribution of hepatic de novo lipid synthesis to new TG 
is rather low comparing to adipose tissue. Thus, even this 
example is enough to stress the importance of adipose tissue 
in the development of pandemics of diet-induced obesity due 
to glucose rich nutrition.
REGIONAL DIFFERNECES IN ADIPOKINE SECRETION
Clinical observations suggest that an abdominal pattern of fat 
distribution with increased visceral fat mass is closely associ-
ated with the adverse cardiometabolic consequences of obesity 
(Fig. 1). There is accumulating evidence that substantial differ-
ences may also exist for the secretory pfofile in subcutaneous
and omental adipose tissue (3,20).
Recent studies have shown that not only is lower-body 
fat accumulation less deleterious than upper-body fat, it may 
actually be protective. Lower-body or peripheral subcutaneous 
fat is negatively associated with cardiometabolic risk factors, 
including insulin resistance, LDL cholesterol, TG, and blood 
pressure, and is associated with protection against atheroscle-
rosis (21). It has been suggested that this might reflect the
ability of lower-body adipose tissue to sequester fatty acids 
(FA) and thus protect other insulin-sensitive tissues from the 
adverse effects of TG accumulation (so-called ectopic fat 
deposition) (22).
































Figure 1. Visceral adiposity and atherosclerosis. Depicted is the significance of visceral obesity as a cause of important
cardiomethabolic risk factors.
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sociated adipose depots have become a focus in the adipobiol-
ogy of inflammation (23), including a possible link between
epicardial adipose tissue and coronary atherosclerosis (23,24). 
It was found that “atherosclerotic” epicardial adipose tissue 
produces an increased amount of nerve growth factor (NGF) 
(2,23 and references therein) and of pro-inflammatory adi-
pokines, whereas a decreased amount of adiponectin (24), a 
potential anti-inflammatory adipokine.
Japanese Sumo wrestlers are very good example to elu-
cidate the significance of regional fat distribution in obesity.
They eat a high energy diet to gain weight but, at same time, 
they are forced to perform strenuous physical training daily. 
Although they showed marked obesity, visceral fat ratio was 
comparable to subcutaneous fat obesity. Their glucose and 
lipid levels are normal. A computer tomograph scan imaging 
at the level of umbilicus demonstrated fat accumulation only in 
the subcutaneous fat obesity and showed marked muscularity. 
The incidence of diabetes increases markedly among retired 
wrestlers who do not continue physical exercise, but remain 
heavy eaters (25,26).
ADIPOSE TISSUE AND INFLAMMATION
An interesting phenomenon is that not all the molecules re-
leased from adipose tissue are produced by adipocytes (3,27-
30). Recent studies suggest that obesity is characterized by 
an accumulation of macrophages in adipose tissue. Adipose 
tissue infiltration by macrophage (3,30, also see Permana in
this volume of Biomedical Reviews) and mast cell (1) appears 
to substantially contribute to the inflamed adipose tissue-trig-
gered release of pro-inflammatory adipokines in obesity and
related CMD (31-36). 
Like macrophages, the adipocyte is exquisitely sensitive to 
infectious disease agents and cytokine-mediated inflammatory
signals. Adipocytes expresse a host of receptors, enabling 
them  to sense the presence of pathogens and inflammatory
signals. This activates multiple inflammatory signal transduc-
tion cascades, and secretes a number of potent inflammatory
adipokines. Adipocytes and resident macrophages contribute 
independently to the local adipose inflammatory output. 
The systemic inflammation observed in obesity is derived 
not only from adipose tissue but also from the liver and other 
important inflammatory tissues. However, even for some of
the proteins derived from the liver, it is believed that adipose 
tissue is the initial driving force for their upregulation. Recent 
studies have led to a major breakthrough in our understanding 
of the origin and the role of tumor necrosis factor-α (TNF-α) 
and other cytokines in obesity. Macrophage accumulation 
occurs in proportion to adipocyte size (32). This adipocyte 
size-related accumulation probably increases the capacity for 
production of proinflammatory and acute phase molecules
that contribute to obesity-related disorders. Thus the obesity 
related increase in macrophages could be largely responsible 
for the major part of TNF-α, IL-1, IL-6, MCP-1 (CCL2), and 
iNOS expression in adipose tissue. Release of macrophage 
TNF-α and IL-6 may contribute to the local decrease in insulin 
sensitivity of adipocytes and to all the other TNF-α- and IL-
6-related disturbances (33-36).
Adipocytes as well as nonfat cells of adipose tissue are now 
recognized as bona fide secretory cell types (1,3,20,27-30). 
Quantitatively, the most important secretion is FA, of which 
there is a net release at periods of negative energy balance, 
particularly fasting and during acute cold exposure. In addition 
to FA, several other lipid moieties are released by fat cells; 
these include prostanoids, which are synthesized by the tis-
sue, and cholesterol and retinol, which are not synthesized but 
rather are stored and subsequently released (35). In addition, 
certain steroid hormone conversions can take place within 
white adipocytes, such as the activation of 11-dehydrocor-
ticosterone (cortisone in humans) into active corticosterone 
(cortisol) catalysed by 11β-hydroxysteroid dehydrogenase 
type 1 (11β HSD-1) (36). When overexpressed in adipocytes 
of transgenic mice, this enzyme induces the complete clinical 
picture of the metabolic syndrome (37), suggesting that the 
inhibition of the activity of 11β HSD-1 may be of a potential 
therapeutic benefit for CMD.
After the identification of leptin as a specific adipocyte-
derived cytokine/hormone, numerous reports have been 
published which clearly established that adipose tissue is 
a multifunctional organ that produces and secretes dozens 




The release of free fatty acids (FFA) from adipose tissue 
regulates systemic FFA concentrations. Under physiological 
conditions, FFA concentrations fluctuate and this is regulated
by the balance between lipolytic and antilipolytic effects in 
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adipose tissue. Antilipolysis as a pharmacological means of 
regulating FFA concentrations is effectively implemented by 
nicotinic acid. The recent demonstration of a G-protein-cou-
pled receptor through which nicotinic acid signals give new 
and mechanistic insight to the action of an old drug (38). The 
expression of the receptor gene in adipose tissue gives the 
mechanistic framework for the antilipolytic action of nicotinic 
acid. In addition, efflux of cholesterol from macrophages is
mediated by the ATP-binding cassette protein A1 (ABCA1) 
transporter; of note, nicotinic acid appears to upregulate the 
ABCA1 gene through cAMP/PKA-dependent pathway (39). 
It is therefore entirely possible that nicotinic acid increases 
the entry of macrophage-derived cholesterol into the HDL 
pool and that this is an antiatherogenic property of nicotinic 
acid which is independent of the TG-lowering effect of the 
drug (38,39).
Based on findings in rodents it has been postulated that
insulin sensitization by the peroxisomal proliferator-activated 
receptor-γ agonists (PPAR-γ) thiazolidinediones (TZDs) de-
pends on lowering of systemic concentrations of FFA. As these 
compounds promote lipogenesis, it is thought that they would 
also promote fat storage in adipose tissue. In humans, however, 
fasting FFA concentrations are not significantly reduced by
rosiglitazone or pioglitazone in patients with T2DM, despite 
a clear insulin-sensitizing effect of these drugs (40).
Clearly, TZDs have a range of effects other than reducing 
systemic concentrations of FFA that contribute to insulin sen-
sitization. These include stimulation of adiponectin secretion 
and receptors, downregulation of inflammatory mediators
derived from adipose tissue and, most probably, exerting 
direct effects on skeletal muscle that are independent of lipid 
transport (41). 
Free fatty acids are a normal physiological fuel. Like 
cholesterol, they are necessary for life and only harmful to 
the organism when present in excessive amounts. Interfering 
with FFA metabolism pharmacologically needs some cau-
tion because reduction of fasting FFA concentrations is not a 
desirable goal. It seems likely that suppressing FFA release 
in the fasting state with the nicotinic acid analogue acipimox 
distresses to body’s energy regulation. A better strategy may 
be to modulate postprandial FFA metabolism (42).
C-reactive protein 
One of the best examples of the clinical marker of systemic 
inflammation is C-reactive protein (CRP). The regulation of
CRP in the liver is believed to be driven by IL-6. It may be 
IL-6 derived from visceral adipose tissue draining directly 
into the portal system that causes the obesity-associated rise 
of liver CRP production (43). In addition to liver-derived CRP, 
newer data show that adipose tissue itself may contribute to 
obesity-associated increased CRP levels (44).
Elevated CRP levels in obesity and the decreases as-
sociated with weight loss provide another suggestive link 
between CRP and obesity-associated risks for CMD. There is 
in vitro evidence demonstrating that CRP also may be an ac-
tive mediator of inflammatory vasculopathy. It was proposed
that the complement-activating and opsonizing activities of 
CRP actually participate in the postinfarction pathology (45). 
Elevated CRP levels have been associated with endothelial 
dysfunction and the activation of endothelial nuclear factor 
kappa-beta (NF-κB). Moreover, a number of pharmacologi-
cal interventions aimed at improving insulin sensitivity (with 
TZDs or metformin), hypertension (angiotensin converting 
enzyme inhibitors), or cholesterol biosynthesis (statins) have 
also been shown to cause significant reductions in CRP levels 
(45,46) (Fig. 2).
ADIPOKINES AS PHARMACOLOGICAL TARGETS 
Plasminogen activator inhibitor-1 
Plasminogen activator inhibitor-1 (PAI-1), although it usually 
derived from platelets and endothelium, is also synthesized in 
both liver and in adipose tissue. Messenger RNAPAI-1 concen-
trations increase up to 10-fold in visceral adipose tissue during 
development of fat accumulation while remains unchanged in 
subcutaneous adipose tissue (48). 
It is not yet known why adipocytes secrete a large amount 
of PAI-1. Adipocytes change their cell size dramatically in 
response to nutritional signals. Although not directly dem-
onstrated, it is possible to assume that adipose PAI-1 overex-
pression may contribute to the elevated risk of obese subjects 
to suffer from thrombembolic complications. Recent studies 
indicate that compounds with anti-inflammatory activity such
as TZDs, metformin and angiotensin II-receptor antagonists 
may reduce adipose PAI-1 production (48).
Tumor necrosis factor-α
Tumor necrosis factor-α (TNF-α) is a proinflammatory cy-
tokine that is involved in the pathogenesis of septic shock, 
autoimmune inflammatory disease, and host defense against
tumors. Hotamisligil et al (49) were the first to describe adipose
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tissue expression of TNF-α and its upregulation in rodent mod-
els of obesity and insulin resistance. Some of the contribution 
of TNF-α to vasculopathic processes may be mostly through 
its involvement in the development of insulin-resistant in 
T2DM (50). Tumor necrosis factor-α is a potent inhibitor of 
adiponectin synthesis, and increased secretion from accumu-
lated visceral adipose tissue may be one of the reasons for the 
reduction of adiponectin in visceral obesity (51).
The animal studies on TNF-α and development of athero-
sclerosis have produced mixed results. Insulin sensitizers, 
TZDs, lower serum TNF-α in human and block TNF-α–me-
diated inhibition of insulin signaling (52). Neutralization of 
TNF-α had no effect on insulin sensitivity in obese, insulin-
resistant subjects (53). More recent observations with the 
TNF-α antibody infliximab, a currently prescribed biological 
to treat rheumatoid arthritis, Crohn’s disease and psoriasis, 
point to a possible benefit also for insulin sensitivity. These
studies suggest that a chronic treatment rather than a single 
administration with TNF-α blocking agent is required to affect 
insulin sensitivity (54). Of note, TNF-α is thought to play a 
role in the progression of ischemia-related congestive heart 
failure; however anti-TNF therapy has shown no benefits for
congestive heart failure progression in patients (55). Whether 
this may be the case for adipose-derived TNF-α-related disor-
ders, remains to be evaluated.
Interleukin-6
Interleukin-6 (IL-6) is long known as a multipotent cytokine. 
Clinical observations suggest that IL-6 may act as a central 
mediator of inflammation in obesity and may be the link to
the increased risk of atherosclerosis (56). Adipose tissue has 
been shown to synthesize and secrete IL-6; it is estimated that 
approximately 25% of the circulating IL-6 originates from the 
adipose tissue. Omental adipose tissue secretes three times as 
much IL-6 as does its subcutaneous counterpart. The direct 
contribution of the adipocytes is only 10%, whereas stro-
mal tissue accounts for 90% of the total IL-6 that is released 
from adipose tissue (57). The high levels of IL-6 are likely 
responsible for the increase in acute-phase proteins, such 
as CRP, observed in obese subjects. Although only minor 
autocrine/paracrine effects of IL-6 have been demonstrated 
in adipose tissue, it appears likely that the elevated adipose 
ACC: Acetyl-CoA carboxylase
CPT: Carnitine palmitoyl transferase
DAG: Diacylglycerol
FAS: Fatty acid synthase






















Figure 2. Hyperglycemia associated lipoapoptosis in the nonadipose cell. Excessive glucose intake stimulates de novo lipogenesis 
producing increased malonyl-CoA, which inhibits the enzyme carnitine palmitoyl transferase 1. Consequently, accumulated 
unoxidized long chain fatty acids in the cytosol cause to lipoapoptosis.
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expression of IL-6 in the obese state is of substantial physi-
ological importance for the crosstalk between adipose tissue 
and distant organs and remains potentially important targets 
for prevention of inflammation-induced insulin resistance
and vasculopathy (58). Further, it was analyzed differentiated 
adipocytes in vitro after statin treatment and found a reduction 
of IL-6 secretion (58). 
Monocyte chemoattractant protein-1 
The chemokine monocyte chemoattractant protein-1 (MCP-1), 
also named CCL2 (cysteine-cysteine motif chemokine ligand 
2), has recently been added to the growing list of adipokines 
(59-63). It recruits monocytes, leukocytes and other inflamma-
tory cells in response to inflammatory challenges. Circulating 
MCP-1 has been found to be increased in obesity and reduced 
after weight loss. This chemokine and its receptor, CCR2, have 
a negative role in adipogenesis and insulin sensitivity (61,62). 
Further, perivascular adipose tissue (23,24) also produces vari-
ous chemokines, suggestive of their paracrine involvement in 
the process of atherogenesis (63).
Current understanding would suggest that treatments that 
prevent macrophage infiltration into obese adipose tissue will 
have beneficial effects on the inflammatory response and the 
abnormal metabolic state. Moreover, the finding that MCP-1
is approximately 7-8 fold higher in the stromovascular fraction 
of adipose tissue (3) and the attenuation of MCP-1 release by 
the anti-diabetic compounds metformin and TZDs supports the 
hypothesis that these drugs exert anti-inflammatory effects and 
thus improve low-grade inflammation in obesity (64).
Angiotensinogen and angiotensin II 
Recent studies showed that adipose tissue may indeed function 
as a jugstaglomerular-like apparatus, secreting all known com-
ponents of renin-angiotensin system. Accordingly, the expres-
sion of angiotensinogen is significantly higher in adipose tissue
from obese as compared to lean subjects. In addition, adipose 
cells from the omental depot produce more angiotensinogen 
than adipocytes from the subcutaneous depot (65).
In humans, angiotensin II (Ang II) was demonstrated to act 
as an inhibitor of adipose tissue differentiation, whereas the 
presence of a selective Ang II receptor antagonist induces adi-
pocyte formation (66). Angiotensin II is also a potent inducer 
of PAI-1 production in human adipocytes and this effect is 
completely abolished by blockade of the Ang II receptor. Thus 
elevated secretion of Ang-II in obesity may contribute to the 
development of hypertension and atherosclerosis (66).
Leptin
In 1994 (67), the paradigm-shifting discovery of adipocyte-de-
rived leptin fundamentally changed our perspective of adipose 
tissue from that of an inert lipid and energy store to an active 
endocrine and metabolic organ that secretes numerous adi-
pokines. Leptin was identified as an adipokine whose absence
resulted in morbid obesity in ob/ob mouse (68-74). Although 
initially hopes were high that leptin would prove important 
in the pathophysiology and thus treatment of human obesity, 
early studies quickly showed that human obesity is generally 
not associated with leptin deficiency (69).
The effect of leptin on lipid metabolism may be mediated 
both through central and peripheral actions of leptin. For 
example, central administration of leptin increased resting 
metabolic rates, resulting in reduced TG content in adipose 
and nonadipose tissues, as well as reduced plasma FFA and 
TG levels (70).
Leptin may also exert autocrine and paracrine effects on 
adipocyte fat metabolism: incubation of mouse adipocytes 
with leptin stimulates lipolysis of intracellular TG. Overex-
pression of leptin in adipocytes also reduced gene expression 
of acetyl CoA carboxylase, which is the rate limiting enzyme 
in de novo lipogenesis. In other tissues, leptin also appears to 
inhibit lipogenesis and stimulate FA oxidation (71). 
Leptin directly stimulates 5’-AMP-activated protein kinase 
(AMPK), which increases ATP-producing catabolic pathways, 
such as beta oxidation of FA, glycolysis, and mitochondrial 
biogenesis, and concomitantly decreases ATP consuming ana-
bolic pathways including the phosphorylation and thereby inhi-
bition of the acetyl CoA carboxylase activity and lipogenesis. 
Leptin also can inhibit the expression of lipogenic transcription 
factor SREBP-1c in liver, pancreatic islets, and adipose tissue, 
thereby inhibiting lipogenesis in those tissues (70,71).
Leptin confines storage of excess calories to adipocytes and
spares the appearance of chronic steatosis in nonadipocyte 
cells. Defective leptin production and action have been pro-
posed to be an important element of the metabolic syndrome. 
Hyperleptinemia in the obese is considered to protect nonadi-
pocytes form lipotoxicity (72). 
Some actions of leptin in high concentrations could be as-
sociated to effects independent of leptin receptor. Crosstalk 
of leptin pathways with other cytokine-related pathways is 
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important in the obesity-related pathologies because of the 
similarities of leptin to the some inflammatory cytokines in-
cluding IL-6. Further, a large prospective study – the West of 
Scotland Coronary Prevention Study (WOSCOPS) – showed, 
for the first time, that leptin might be an independent risk factor
for coronary heart disease (73).
Leptin plays a physiological role but leptin resistance may 
be of pathophysiological significance for cardiometabolic
dysfunctions in obesity. Lipoapoptosis is a metabolic cause of 
tissue injury and death in obesity (74,75). Leptin is capable of 
oxidizing excessive long-chain FA to improve cardiac func-
tion. However, the leptin-induced FA oxidation may become 
inefficient under hyperleptinemia or leptin resistance, allowing
unoxidized FA to enter nonoxidative pathways, eventually 
leading to cellular injury. Leptin-induced liporegulation serves 
to prevent lipid accumulation and lipoapoptosis (Fig. 3). Dis-
ruption of liporegulation in response to leptin is hypothesized 
to be essential under hyperleptinemia and may attribute to the 
metabolic syndrome in obesity (72).
Leptin supplementation is currently used clinically to treat 
patients with congenital leptin deficiency. Leptin deficiency
is also found in acquired and inherited lipodystropies, which 
are associated with severe insulin resistance, dyslipidemia and 
hepatic steatosis as stated above. Leptin-replacement therapy 
in these patients leads to a correction of the hyperglycemia 
and a reduction in plasma lipids, thus helping to minimize the 
risk of metabolic complications (76).
Adenovirus-induced hyperleptinemia promotes a dramatic 
reduction of white adipocyte size in rats, and the FA are oxi-
dized directly inside the adipocytes that become able to burn 
fat (77). Physiological and therapeutic importance of this 
observation needs further studies.
Adiponectin
Adiponectin is thus far the best-studied adipokine until now. 
Although there are extra-adipose sources of adiponectin, the 
adipocytes are the most important producer of this multipoten-
tial adipokine. Today, adiponectin is promising a large number 
of therapeutic benefits, including many “anti-” effects, such as
anti-inflammatory, anti-atherogenic, anti-diabetic, anti-obesity,
and anti-cancer effects (25,78-84). 
Very strong negative correlation is found between the 
adiponectin level and visceral adiposity. The mechanism 
for the reduction of plasma adiponectin levels in individu-
als with visceral fat accumulation has not yet been clarified.
However, some findings suggest that some inhibiting factors
for adiponectin synthesis or secretion are secreted from vis-
ceral adipose tissue. Most probably, the increased secretion 
of TNF-α from accumulated visceral fat is responsible for this 
negative correlation (79).
Plasma adiponectin concentrations are lower in people 
with T2DM, and high adiponectin concentration was a no-
table protective factor against development of this disease. 
Likewise, plasma concentrations of adiponectin are lower in 
patients with coronary heart disease and with the metabolic 
syndrome (80). In a prospective study it is confirmed that high
adiponectin concentrations are associated with reduced risk of 
acute myocardial infarction in men (81).
Adiponectin administration enhanced hepatic insulin action 
and reduced liver gluconeogenesis and lipid accumulation in 
nonadipose tissues. Glucose uptake and FA oxidation were in-
creased, whereas lipid accumulation was decreased in skeletal 
muscle. Adiponectin effects are mediated by AMPK, which 
has been reported to increase FA oxidation during muscle 
contraction and repress key enzymes of gluconeogenesis in 
hepatocytes. AMPK is known to mediate the insulin sensitizing 
action of exercise, some antidiabetic effects of metformin, and 
leptin action on skeletal muscle (82).
The clinical and experimental evidence of adiponectin's 
multibeneficial effects might lead to the development of new 
therapeutic strategies for CMD (1,2,23,24,31,78-81,83,84). 
For instance, human recombinant adiponectin and/or adi-
ponectin-mimetic compounds acting less or more specifically
on adiponectin receptor subtypes might be new therapeutic 
approaches. Likewise, boosting adiponectin secretion in adi-
pocyte and extra-adipose sources by small molecules appears 
to be a promising pharmacological strategy (84 for PPARγ 
agonists). For more information about adiponectin biology 
and pharmacotherapy, see Shimomura et al and Cheng et al 
in this volume of Biomedical Reviews.
Resistin
Resistin (FIZZ-3, found in inflammatory zone-3) received
its name from the original observation that it induced insulin 
resistance in mice. In humans, the role of resistin is even less 
certain. Some investigators reported low to undetectable ex-
pression of resistin in adipose tissue, whereas it is expressed 
at higher levels in macrophages (85). The role of resistin in 
human insulin resistance remains quite controversial. How-
ever, in humans, resistin seems to act as a critical mediator 
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of the insulin resistance associated with sepsis and possibly 
other inflammatory conditions (86).
ADIPOPHARMACOLOGY OF CURRENTLY USED DRUGS 
Thiazolidinediones
The most prominent examples of drugs favoring a healthy 
adipokine profile are the TZDs represented by PPAR-γ ago-
nists. Various beneficial cardiometabolic effects reported for
PPARγ agonists are thought to result from direct actions on 
adipose tissue, along with secondary impact on skeletal mus-
cle and liver. The beneficial actions of PPARγ agonists on 
muscle, liver, and blood vessels are mediated by their ability 
to (i) improve the insulin-mediated uptake and metabolism of 
glucose and FFA in the adipocyte, (ii) increase the secretion of 
adiponectin, and (iii) reduce the production of factors leading 
to insulin resistance, such as TNF-α and resistin (87,88). The 
role of the TZDs rosiglitazone and pioglitazone in the treat-
ment of T2DM is well established. The anti-inflammatory
effects of TZDs may partly be mediated by their beneficial 
effects on dyslipidemia, but there is also evidence that TZDs 
may directly modulate inflammation via transcription factors 
such as NF-κB (89).
Statins
Statins were introduced and then widely used for the 
management of plasma cholesterol levels in patients with 
atherosclerotic cardiovascular disease. This class of drugs 
comprises inhibitors of 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG-CoA) reductase, an enzyme involved in cholesterol 
biosynthesis primarily in the liver. Importantly, statins may 
affect therapeutically not only cholesterol levels, but many 
other processes such as various cellular events in atherogen-
esis and inflammation (90) and even T2DM-linked cognitive
dsyfunction (91,92). 
As outlined above, the reduction of general inflamma-
tory markers is advisable for the reduction of cardiovascular 
events along with an improvement of the lipoprotein profile.
C-reactive protein is expressed in adipose tisue, but this tissue 
is unlikely to be a major systemic source for this protein. An 
alternative explanation is that statins might achieve some of 
their beneficial effects by altering the composition of adipocyte
plasma membranes and/or the secretion of adipokines (58). 
In the context of obesity and adipose-derived inflammation,
it was reported that statins may have direct anti-inflammatory
actions on adipocytes themselves (93) (Fig. 2). Treatment of 
cultured adipocytes with cerivastatin decreased expression and 
secretion of the pro-inflammatory adipokine IL-6 (58). Further
studies may clarify the possible statin-adiponectin interactions 
and their implications for the therapy of adiponectin-associ-
ated diseases.
Adipocytes have very important functions in cholesterol 
homeostasis. Adipose tissue contains the largest pool of free 
cholesterol in the body. Adipocytes can uptake and degrade 
oxidized LDL (Ox-LDL) while such an ability was impaired 
under hypercholesterolemic condition (94). Speculatively, stat-
ins might increase uptake of ox-LDL by reducing cholesterol 
level and changing the transcriptional ability of adipocytes 
(95).
NEW TARGETS FOR ADIPOPHARMACOLOGY
5’-AMP-activated protein kinase 
5’-AMP-activated protein kinase (AMPK) is a heterotrimeric 
enzyme that is conserved from yeast to humans and function 
as a “fuel gauge” to monitor cellular energy status. AMPK 
stimulates pathways which increase energy production 
(glucose transport, FA oxidation) and switches off pathways 
which consume energy (lipogenesis, protein synthesis, gluco-
neogenesis). Activation of AMPK leads to phosphorylation, 
and thus inhibition of CoA carboxylase (82). The latter is the 
regulated step in malonyl-CoA production and subsequent 
FA biosynthesis. Malonyl-CoA is also a potent inhibitor of 
carnitine palmitoyl transferase-1, the rate-limiting enzyme 
of FA uptake into the mitochondria. Therefore, a reduction in 
malonyl-CoA removes inhibition of mitochondrial FA uptake 
and stimulates FA oxidation, as well as reduces lipid biosyn-
thesis (22) (Fig. 3). 
Adipose tissue is a major component of energy homeostasis 
and a key player in the regulation of insulin sensitivity through 
FA release and hormone secretion. Thus, it is clear that the 
function of AMPK in adipocytes should be crucial for the regu-
lation of energy metabolism through the release of substrates 
and hormones involved in metabolism. While activation of 
adipose AMPK can be achieved through fasting and exercise 
(96), no pharmacological agents for treating obesity and obes-
ity-associated diseases have been reported in targeting AMPK 
until now. Of note, two compounds that are widely used in 
the therapy of T2DM, metformin and rosiglitazone, have been 
demonstrated to activate AMPK (97).
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ADIPOSE TISSUE AND LONGEVITY
Aging is a multiplex phenomenon characterized by the decay 
of biological function over time, eventually leading to the 
development of various desease. Adipose tissue seems to be a 
pivotal organ in aging processes and in determination of lifespan 
(98). Calorie restriction (CR) is the most robust, nongenetic 
intervention that increases lifespan and reduces the rate of aging 
in a variety of species (99-101). Mechanisms responsible for 
the anti-aging effects of CR remain uncertain, but reduction of 
reactive oxygen species (ROS) within mitochondria remains a 
major focus of research. Specifically, both in vivo and in vitro 
analyses have demonstrated that CR attenuates ROS-medi-
ated damages (102), also stimulates mitochondrial biogenesis 
through induction of endothelial nitric oxide synthase expression 
in various tissues of mice (103, also via sirtuin-1 upregulation). 
In effect, mitochondria may play a pivotal role in the life of cells, 
controlling diverse processes ranging from energy production to 
apoptosis (104). Further, small molecules including xenohormet-
ics (105-107) may provide a benefit to aging and related diseases
including Alzheimer’s disease (106,107). Fat-specific disruption
of the insulin receptor gene mice demonstrates the important role 
of reduced adiposity and suggests a special role for the insulin 
signaling pathway in adipose tissue in the longevity process 
(108). The effect of adipose tissue reduction on lifespan could 
be due to the production of adipokines acting on target tissues, or 
due to the indirect prevention of age-related metabolic disorders 
like T2DM or atherosclerosis (see 91,92).
Sirtuin 1, an ortholog protein encoded by the life-extending 
yeast gene silent information regulator 2 (Sir2), is involved 
in the molecular mechanisms linking lifespan to adipose tis-
sue. In mature adipocytes, stimulation of sirtuin 1 activity by 
a small molecule, resveratrol (found in red grapes and red 
wine), promotes lipolysis and a reduction in adipose tissue 










Figure 3. Anti-inflammatory action of statins. Inflamatory molecules, IL-6 and TNF-α, are under the inhibitory control of 
adipocyte transcripton factor PPARγ. Statins stimulate the activity of  PPARγ and suppress the production of these proinflamatory
adipokines. CRP, C-reactive protein.
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CONCLUSION AND A DREAM
The adipose tissue is now increasingly recognized not solely 
as lipid and energy storage but also as an active endocrine and 
paracrine organ, secreting a large number of adipokines, and 
also steroid hormones, fatty acids, and prostaglandins. There 
is overwhelming evidence that adipose tissue is at the center 
of dysfunctional regulatory cascades in many diseased states, 
ranging from CMD, fatty liver diseases, polycystic ovary syn-
drome, cancer, and Alzheimer’s disease (type 3 diabetes?). To-
day, it is also extremely important to understand if this adipose 
dysfunction can be restored by dietary intervention and/or by 
pharmacological treatment. Whatever the research outcomes 
and possible discoveries, Paul Ehrlich’s “magic bullets” in the 
adipopharmacology of disease will continue to be a dream of 
Homo obesus and his accompanying diseases.
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